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response (CR), 2 partial responses (PR), and 8 patients with stable dis-
ease (SD). The patient with the CR has been maintained on BIBF 1120 
monotherapy for a period of over 52 weeks.
Conclusions: The combination of BIBF 1120 and pemetrexed in previ-
ously treated NSCLC patients was shown to be safe and well tolerated 
in this study. The MTD of BIBF 1120 was 200 mg bid when given with 
pemetrexed at 500 mg/m2. Signs of clinical efﬁcacy were observed in 
the small number of patients treated in this trial.
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Background: Advanced stage NSCLC patients (pts) with a PS of 2 
have inferior outcomes compared to good PS pts. No consensus exists 
on the most appropriate management approach, with options ranging 
from supportive care alone to platinum-based combination chemo-
therapy. SWOG has recently completed two trials (S0027) and (S0341) 
evaluating the value of sequential single agent chemotherapy and the 
EGFR tyrosine kinase inhibitor erlotinib (E) respectively in unselected 
pt populations with PS 2. This report details a comparative analysis of 
these two treatment approaches.
Methods: Eligibility: stage III B (pleural effusion)/IV NSCLC; PS 2; 
measurable disease (S0341), measurable + evaluable disease (S0027); 
no prior chemotherapy/biologic treatment. Pts > age 70 with PS 0-1 
also eligible for S0027 but this strata not included in this analysis. 
Treatment: (S0027) vinorelbine 25 mg/m2 d 1,8 q 21 d for 3 cycles then 
docetaxel 35 mg/m2 d1,8,15 q 28 d for 3 cycles; (S0341) E 150 mg 
orally daily.
Results: (S0027, S0341): Eligible patients: 42, 73; median age 73, 74; 
M/F (%) 55/45, 47/53; stage IIIB/IV (%) 15/85, 12/88, respectively. 
Response rate (RR), disease control rate{response + stable disease} 
(DCR), progression free survival (PFS), median survival (MST) and 
toxicity - see table.
Conclusions: Outcome with sequential single agent chemotherapy 
or single agent erlotinib remains poor in advanced NSCLC pts with 
PS 2. Overall tolerance of treatment appeared to be more favorable in 
pts receiving erlotinib. Better patient selection employing an EGFR 
biomarker strategy may improve results with E and result in a superior 
outcome to chemotherapy in this selected patient population. This 
concept is now being explored within SWOG.
S0027(N=42) S0341(N=73)
Response Rates:  
Complete/Partial 0%/11% (N=37) 1%/7% (N=72)
Disease Control Rate: 
Response+Stable Disease 38% (N=37) 43% (N=72)
PFS/MST (95% C I) 2.6(1.9-4.2)/ 5.5(3.1-6.5) 2.1(1.5-3.1)/ 5(3.5-7.3)
Grade 3/4 AE’s(%) 48/26 33/7
Grade 5 AE(%) 4.8 1.4
P3-093 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Correlative analyses of plasma cytokine / angiogenic factor (C/AF) 
profile, gender and outcome in a randomized, three-arm, phase 
II trial of 1st-line vandetanib (VAN) and / or carboplatin plus 
paclitaxel (CP) for advanced non small cell lung cancer (NSCLC).
Heymach, J V.1 Hanrahan, E O.1 Lin, H Y.1 Du, D Z.1 Yan, S1 Kim, E S.1 
Lee, J J.1 Ryan, A J.2 Tran, H T.1 Johnson, B E.3 
1 University of Texas M.D. Anderson Cancer Center, Houston, TX, 
USA 2 AstraZeneca, Macclesfield, UK 3 Dana-Farber Cancer Institute, 
Boston, MA, USA 
Background: VAN (ZD6474) is an oral inhibitor of VEGFR, EGFR 
and RET. In a phase II trial, 181 patients with advanced NSCLC were 
randomized to 1st-line treatment with VAN, CP or VAN + CP. Progres-
sion free survival (PFS) was prolonged for VAN + CP vs CP (Heymach 
et al, Proc ASCO 2007). Exploratory subgroup analyses suggest gender 
differences in PFS beneﬁt for VAN + CP vs CP (HR 0.47 in females vs 
1.05 in males). We performed exploratory analyses of plasma levels of 
35 C/AFs to investigate gender differences and potential prognostic or 
predictive markers.
Methods: Plasma was collected at baseline (n = 123; VAN 55, CP 32, 
VAN + CP 36), day (D) 8 (n = 104), D22 (n = 95), and D43 (n = 83). 
We used multiplex bead assays to measure 33 plasma C/AFs, including 
VEGF, basic FGF, EGF, HGF, E-selectin, ICAM-1, MMP-9, multiple 
chemokines and interleukins (IL). Osteopontin and sVEGFR-2 were 
measured by ELISA. Cox models were applied on PFS to identify 
prognostic / predictive markers after rank transformation and adjusted 
for covariates.
Results: Signiﬁcant gender differences in baseline C/AF levels were 
seen for IL-15, IL-1RA, IL-2R, MIG, and MIP-1α (all higher in 
females, all p <.022). During treatment, signiﬁcant changes in median 
VEGF levels (102 pg/mL at baseline, 127 pg/mL at day 43, p = .041) 
and sVEGFR-2 levels (9593 pg/mL at baseline, 7696 pg/mL at day 43, 
p = .027) occurred in the VAN arm. IL-12, IL-1RA, MMP-9 and MCP-
1 levels were modulated in the CP and VCP arms. High baseline E-
selectin (p = .01), IL-6 (p = .018), and sIL-2R (p = .008) were negative 
prognostic indicators for PFS. Tests for treatment by factor interactions 
(assessing if treatment effect was different in patients with low and 
high levels of a factor), including all 3 treatment arms, were signiﬁcant 
for baseline HGF (p = .04) and sIL-2R (p = .008). Low levels of HGF 
and sIL-2R were predictive of prolonged PFS in the VAN arm, but not 
in the CP or VAN+CP arms. When only the VAN+CP and CP arms 
were considered, the tests for treatment by factor interaction were of 
borderline signiﬁcance for baseline ICAM-1, sVEGFR-2, MMP-9 and 
EGF. Low ICAM-1, sVEGFR-2, and MMP-9, and high EGF were as-
sociated with greater PFS in the VCP arm, but not in the CP arm. 
Conclusions: There are gender differences in PFS beneﬁt from VAN 
and in plasma C/AF proﬁle. Several C/AFs were of prognostic value, 
whereas low HGF and IL-2R were predictive of beneﬁt in the VAN 
but not CP and VAN + CP arms. This study suggests that broad-based 
plasma proﬁling of cytokines and angiogenic factors may be feasible 
approach for identifying prognostic and predictive markers of beneﬁt 
for different therapies. Further investigation of these biomarkers is 
warranted. 
